AstraZeneca starts new study of heart drug Brilinta
LONDON, July 17
LONDON, July 17 (Reuters) - AstraZeneca is to conduct a new global clinical trial of its heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain's second biggest drugmaker said on Tuesday.
Peripheral artery disease affects around 27 million people in Europe and North America. Sufferers are at high risk of heart attacks, strokes and other complications.
The new study will compare AstraZeneca's medicine, which is currently only approved for patients with acute coronary syndromes, against its older rival Plavix.
- Trucks from aid convoy to Ukraine start crossing back into Russia |
- Restraint marks Ferguson, Missouri protests for third straight night |
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- U.S. hostage rescuers dropped from night sky: Syria activist